{"id":{"repo_id":"houston","oai_identifier":"oai:uh-ir.tdl.org:10657/1070"},"canonical_url":"https://search.dev.ndltd.org/etd/houston/oai:uh-ir.tdl.org:10657/1070","repository":{"repo_id":"houston","name":"University of Houston","base_url":"https://uh-ir.tdl.org/server/oai/request"},"display":{"title":"Comparative Effectiveness of Smoking Cessation Medications among Obese Smokers","abstract":"Objective I: To compare the continuous abstinence rates of FDA-approved smoking cessation medication strategies during a) 3 months, b) 6 months, and b) 12 months follow up period among obese smokers. Hypothesis (Ha): Abstinence rates among obese smokers using varenicline will be higher compared to obese smokers using bupropion during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective II: To compare the post-cessation weight gain between the two FDA-approved smoking cessation medications during: a) 3 months, b) 6 months, and c) 12 months of follow up period. Hypothesis (Ha): Obese smokers using bupropion experience lesser weight gain compared to those obese smokers using varenicline during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective III: To compare the risk of developing diabetes following smoking cessation during the first year follow up among obese smokers between the FDA-approved smoking cessation medications (bupropion and varenicline). Hypothesis (Ha): Obese smokers using bupropion are less likely to develop diabetes following smoking cessation during a 1-year follow up compared to those using varenicline.","abstract_html":"Objective I: To compare the continuous abstinence rates of FDA-approved smoking cessation medication strategies during a) 3 months, b) 6 months, and b) 12 months follow up period among obese smokers. Hypothesis (Ha): Abstinence rates among obese smokers using varenicline will be higher compared to obese smokers using bupropion during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective II: To compare the post-cessation weight gain between the two FDA-approved smoking cessation medications during: a) 3 months, b) 6 months, and c) 12 months of follow up period. Hypothesis (Ha): Obese smokers using bupropion experience lesser weight gain compared to those obese smokers using varenicline during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective III: To compare the risk of developing diabetes following smoking cessation during the first year follow up among obese smokers between the FDA-approved smoking cessation medications (bupropion and varenicline). Hypothesis (Ha): Obese smokers using bupropion are less likely to develop diabetes following smoking cessation during a 1-year follow up compared to those using varenicline.","abstract_has_math":false,"creators":["Yang, Mo 1985-"],"institution":"University of Houston","degree_name":"Doctor of Philosophy","degree_level":"Doctoral","degree_discipline":"Pharmacy Administration","degree_department":null,"school":null,"contributors":[],"advisors":["Abughosh, Susan M."],"committee_chairs":[],"committee_members":["Chen, Hua","Johnson, Michael L.","Essien, Ekere James","Peters, Ronald J."],"year":2013,"date_issued":"2013-08","date_published":"2013-08","updated_at":"2026-07-24T02:32:54Z","subjects":["Comparative effectiveness","Smoking cessation","Abstinence rate","Obesity","Weight Change","Type 2 Diabetes","Varenicline","Bupropion"],"languages":["eng"],"rights":["The author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s)."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10657/1070","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Abughosh, Susan M."]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Chen, Hua","Johnson, Michael L.","Essien, Ekere James","Peters, Ronald J."]},{"key":"dc:creator","label":"Author","values":["Yang, Mo 1985-"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2015-08-25T01:40:11Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2015-08-25T01:40:11Z"]},{"key":"dc:date.issued","label":"Date","values":["2013-08"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmacy Administration"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Houston"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Comparative effectiveness","Smoking cessation","Abstinence rate","Obesity","Weight Change","Type 2 Diabetes","Varenicline","Bupropion"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["The author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s)."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10657/1070"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Objective I: To compare the continuous abstinence rates of FDA-approved smoking cessation medication strategies during a) 3 months, b) 6 months, and b) 12 months follow up period among obese smokers. Hypothesis (Ha): Abstinence rates among obese smokers using varenicline will be higher compared to obese smokers using bupropion during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective II: To compare the post-cessation weight gain between the two FDA-approved smoking cessation medications during: a) 3 months, b) 6 months, and c) 12 months of follow up period. Hypothesis (Ha): Obese smokers using bupropion experience lesser weight gain compared to those obese smokers using varenicline during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective III: To compare the risk of developing diabetes following smoking cessation during the first year follow up among obese smokers between the FDA-approved smoking cessation medications (bupropion and varenicline). Hypothesis (Ha): Obese smokers using bupropion are less likely to develop diabetes following smoking cessation during a 1-year follow up compared to those using varenicline."]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Comparative Effectiveness of Smoking Cessation Medications among Obese Smokers"]}]}],"canonical_facts":{"dc:contributor.advisor":["Abughosh, Susan M."],"dc:contributor.committeemember":["Chen, Hua","Johnson, Michael L.","Essien, Ekere James","Peters, Ronald J."],"dc:creator":["Yang, Mo 1985-"],"dc:date.accessioned":["2015-08-25T01:40:11Z"],"dc:date.available":["2015-08-25T01:40:11Z"],"dc:date.issued":["2013-08"],"dc:description.abstract":["Objective I: To compare the continuous abstinence rates of FDA-approved smoking cessation medication strategies during a) 3 months, b) 6 months, and b) 12 months follow up period among obese smokers. Hypothesis (Ha): Abstinence rates among obese smokers using varenicline will be higher compared to obese smokers using bupropion during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective II: To compare the post-cessation weight gain between the two FDA-approved smoking cessation medications during: a) 3 months, b) 6 months, and c) 12 months of follow up period. Hypothesis (Ha): Obese smokers using bupropion experience lesser weight gain compared to those obese smokers using varenicline during a)3, b)6, and c)12 month follow-up after treatment initiation. Objective III: To compare the risk of developing diabetes following smoking cessation during the first year follow up among obese smokers between the FDA-approved smoking cessation medications (bupropion and varenicline). Hypothesis (Ha): Obese smokers using bupropion are less likely to develop diabetes following smoking cessation during a 1-year follow up compared to those using varenicline."],"dc:format.mimetype":["application/pdf"],"dc:identifier.uri":["http://hdl.handle.net/10657/1070"],"dc:language.iso":["eng"],"dc:rights":["The author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s)."],"dc:subject":["Comparative effectiveness","Smoking cessation","Abstinence rate","Obesity","Weight Change","Type 2 Diabetes","Varenicline","Bupropion"],"dc:title":["Comparative Effectiveness of Smoking Cessation Medications among Obese Smokers"],"thesis:degree_discipline":["Pharmacy Administration"],"thesis:degree_level":["Doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["University of Houston"]},"updated_at":"2026-07-24T02:32:54Z"}